<DOC>
	<DOCNO>NCT01530529</DOCNO>
	<brief_summary>The purpose study assess bioavailability , safety , tolerability modified-release formulation PF-05180999 relative immediate-release formulation healthy adult subject . Two dose modified-release formulation one dose immediate-release formulation evaluate fasted condition . One dose modified-release formulation also evaluate presence food .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability Modified-Release Formulation PF-05180999</brief_title>
	<detailed_description />
	<criteria>Male female nonchildbearing potential Evidence clinicallysignificant medical illness , history seizure , condition possibly affect drug absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>PF-05180999</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Schizophrenia Disorders Psychotic Features</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>